NLRP3 and metabolic dysfunction-associated steatotic liver disease: For that reason, this study was conducted in ApoE-/- mice, which have a genetic predisposition to develop chronic inflammation (Harja et al., 2008), including metabolic syndrome (Schierwagen et al., 2015) as a useful tool to explore the therapeutic effects of a novel selective NLRP3 antagonist in lean NAFLD.